Cargando…

Tumor lenvatinib addiction and withdrawal rebound response in patients with advanced endometrial cancer

Combination therapy of lenvatinib, a multitargeted tyrosine kinase inhibitor (TKI), plus pembrolizumab, a monoclonal antibody targeting programmed death receptor 1 (PD-1), was recently approved by the Food and Drug Administration for therapy of advanced endometrial cancer. This case series highlight...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lam, Clarissa, Sarasohn, Debra, Weigelt, Britta, Zamarin, Dmitriy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Case Series
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10448068/ https://www.ncbi.nlm.nih.gov/pubmed/37636495 http://dx.doi.org/10.1016/j.gore.2023.101258

Ejemplares similares

Sustained response to lenvatinib and pembrolizumab in two patients with KRAS-mutated endometrial mesonephric-like adenocarcinoma
por: Shen, Sherry, et al.
Publicado: (2021)

Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer
por: Makker, Vicky, et al.
Publicado: (2020)

Activity of pembrolizumab and lenvatinib in mismatch repair deficient (dMMR) endometrial cancer patients who have failed pembrolizumab monotherapy: A case series
por: Rose, Peter G., et al.
Publicado: (2023)

Modified Hepatic Arterial Infusion Chemotherapy Combined with Lenvatinib and Camrelizumab for Advanced HCC: Two Case Reports
por: Tian, Yuan, et al.
Publicado: (2023)

Lenvatinib plus pembrolizumab in patients with advanced or recurrent uterine carcinosarcoma
por: Hunt, Jonathan T., et al.
Publicado: (2021)

Dramatic rebounds of MS during pregnancy following fingolimod withdrawal
Publicado: (2018)

Dramatic rebounds of MS during pregnancy following fingolimod withdrawal
por: Novi, Giovanni, et al.
Publicado: (2017)

Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma
por: Lorusso, Domenica, et al.
Publicado: (2022)

Corrigendum: Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma
por: Lorusso, Domenica, et al.
Publicado: (2023)

Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 study
por: Rubinstein, Maria M., et al.
Publicado: (2023)

Unbearable Pruritus After Withdrawal of (Levo)cetirizine
por: Ekhart, Corine, et al.
Publicado: (2016)

To rebound or not to rebound
por: Stahl, Bethany A, et al.
Publicado: (2017)

Response to lenvatinib and pembrolizumab combination therapy in pembrolizumab-pretreated relapsed endometrial cancer
por: Mimura, Kaito, et al.
Publicado: (2022)

Dependence, withdrawal and rebound of CNS drugs: an update and regulatory considerations for new drugs development
por: Lerner, Alicja, et al.
Publicado: (2019)

Characterization and Management of Adverse Reactions in Patients with Advanced Endometrial Carcinoma Treated with Lenvatinib Plus Pembrolizumab
por: Makker, Vicky, et al.
Publicado: (2021)

Esophagitis as a complication of the combination of lenvatinib and pembrolizumab for advanced endometrial cancer: A case report
por: Fellouah, Massine, et al.
Publicado: (2023)

Pembrolizumab plus lenvatinib in advanced endometrial cancer: case report and systematic review of lung toxicity
por: Staropoli, Nicoletta, et al.
Publicado: (2023)

Postablation Endometrial Carcinoma
por: Wortman, Morris, et al.
Publicado: (2017)

Chemotherapy alone may have equivalent survival as compared to suboptimal surgery in advanced endometrial cancer patients
por: Rauh, Lisa, et al.
Publicado: (2020)

Genomic profiling of endometrial cancer and relationship with volume of endometrial cancer disease spread
por: Sullivan, Stephanie A., et al.
Publicado: (2021)

Endometrioid adenocarcinoma associated with endometrial stromal sarcoma: A rare, often unrecognized collision tumor
por: Kim, Grace, et al.
Publicado: (2015)

Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors
por: Taylor, Matthew H., et al.
Publicado: (2020)

Lenvatinib-Induced Tumor Lysis Syndrome in Advanced Hepatocellular Carcinoma
por: Goyal, Manjeet Kumar, et al.
Publicado: (2023)

Risk factors and sonographic endometrial thickness as predictors of tumour stage and histological subtype of endometrial cancer
por: Rizzuto, Ivana, et al.
Publicado: (2019)

Dupilumab in the management of topical corticosteroid withdrawal in atopic dermatitis: A retrospective case series
por: Arnold, Kathryn A., et al.
Publicado: (2018)

Suspected benzodiazepine withdrawal‐associated seizures in 3 young dogs undergoing mechanical ventilation
por: Walton, Rebecca A. L., et al.
Publicado: (2022)

Hypersexuality Addiction and Withdrawal: Phenomenology, Neurogenetics and Epigenetics
por: Blum, Kenneth, et al.
Publicado: (2015)

Hypersexuality Addiction and Withdrawal: Phenomenology, Neurogenetics and Epigenetics
por: Blum, Kenneth, et al.
Publicado: (2015)

The role of endometrial sampling for surveillance of recurrence in postmenopausal patients with medically inoperable stage I endometrial cancer
por: Carey-Love, Angelina, et al.
Publicado: (2020)

Impact of lower uterine segment involvement in type II endometrial cancer and the unique mutational profile of serous tumors
por: Kogan, Liron, et al.
Publicado: (2018)

Lenvatinib Plus Pembrolizumab vs. Chemotherapy in Pretreated Patients With Advanced Endometrial Cancer: A Cost-Effectiveness Analysis
por: Feng, Mingyang, et al.
Publicado: (2022)

Case Report: Persisting Lymphopenia During Neuropsychiatric Tumefactive Multiple Sclerosis Rebound Upon Fingolimod Withdrawal
por: Koska, Valeria, et al.
Publicado: (2021)

Case Report: Severe rebound after withdrawal of fingolimod in a patient with neuromyelitis optica spectrum disorder
por: Lin, Wei, et al.
Publicado: (2023)

Withdrawal of bevacizumab is associated with rebound growth of vestibular schwannomas in neurofibromatosis type 2-related schwannomatosis patients
por: Webb, M J, et al.
Publicado: (2023)

Improved indocyanine green retention after short-term lenvatinib withdrawal in three patients with hepatocellular carcinoma
por: Sugimoto, Rie, et al.
Publicado: (2021)

Machine learning-based prediction of microsatellite instability and high tumor mutation burden from contrast-enhanced computed tomography in endometrial cancers
por: Veeraraghavan, Harini, et al.
Publicado: (2020)

Correction: Hypersexuality Addiction and Withdrawal: Phenomenology, Neurogenetics and Epigenetics
por: Blum, Kenneth, et al.
Publicado: (2015)

Retraction: Hypersexuality Addiction and Withdrawal: Phenomenology, Neurogenetics and Epigenetics
por: Blum, Kenneth, et al.
Publicado: (2015)

Oral health behavior of drug addicts in withdrawal treatment
por: Shekarchizadeh, Hajar, et al.
Publicado: (2013)

LGG-17. Preventing recurrence: targeting molecular mechanisms driving tumor growth rebound after MAPKi withdrawal in pediatric low-grade glioma
por: Kocher, Daniela, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_q1hhs0rmc9garads80crajoue4